- Home
- APRE vs NRSN Comparison
APRE vs NRSN Comparison
Compare APRE & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- NRSN
- Stock Information
- Founded
- APRE 2006
- NRSN 2017
- Country
- APRE United States
- NRSN Israel
- Employees
- APRE N/A
- NRSN N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- APRE Health Care
- NRSN Health Care
- Exchange
- APRE Nasdaq
- NRSN Nasdaq
- Market Cap
- APRE 15.8M
- NRSN 17.8M
- IPO Year
- APRE 2019
- NRSN 2021
- Fundamental
- Price
- APRE $4.08
- NRSN $1.08
- Analyst Decision
- APRE Strong Buy
- NRSN Hold
- Analyst Count
- APRE 2
- NRSN 1
- Target Price
- APRE $15.50
- NRSN N/A
- AVG Volume (30 Days)
- APRE 33.0K
- NRSN 336.3K
- Earning Date
- APRE 11-07-2024
- NRSN 12-18-2024
- Dividend Yield
- APRE N/A
- NRSN N/A
- EPS Growth
- APRE N/A
- NRSN N/A
- EPS
- APRE N/A
- NRSN N/A
- Revenue
- APRE $1,310,839.00
- NRSN N/A
- Revenue This Year
- APRE $134.21
- NRSN N/A
- Revenue Next Year
- APRE N/A
- NRSN N/A
- P/E Ratio
- APRE N/A
- NRSN N/A
- Revenue Growth
- APRE 130.31
- NRSN N/A
- 52 Week Low
- APRE $2.15
- NRSN $0.51
- 52 Week High
- APRE $8.85
- NRSN $2.33
- Technical
- Relative Strength Index (RSI)
- APRE 62.50
- NRSN 48.25
- Support Level
- APRE $3.34
- NRSN $1.01
- Resistance Level
- APRE $4.41
- NRSN $1.13
- Average True Range (ATR)
- APRE 0.43
- NRSN 0.08
- MACD
- APRE 0.04
- NRSN -0.01
- Stochastic Oscillator
- APRE 54.19
- NRSN 34.48
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.